Partnership to Target Tuberculosis

The Woolcock has partnered with Pharmaxis, a medical device company with a high-payload inhaler, to develop novel approaches to treat Tuberculosis. Members of the Respiratory Technology and Respiratory and Environmental Epidemiology groups at the WIMR are working together with Pharmaxis to develop an inhalable therapy for TB to be used in developed and developing countries.

To learn more about our vision for treating TB you can watch the video by clicking on the image above or following the link: http://vimeo.com/respitech/targeting-tuberculosis

You can learn more about the Woolcock Institute of Medical Research,  clinics and research at www.woolcock.org.au. Learn more about the Respiratory Technology team at the Woolcock at www.RespiTech.org. And don't forget to like RespiTech at www.Facebook/RespiTech. and follow us on twitter